Remdesivir for the treatment of COVID-19: a Cochrane review

Affiliations

• ¹ Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, Alemania. Contribuyó de igual forma que los primeros autores.
• ² Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Alemania. Contribuyó de igual forma que los primeros autores.
• ³ Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, Alemania.
• ⁴ Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Alemania.
• ⁵ Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Alemania.
• ⁶ Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Alemania.
• ⁷ Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Alemania.
• ⁸ Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, Alemania. Contribuyó de igual forma que los últimos autores.
• ⁹ Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Alemania. Contribuyó de igual forma que los últimos autores.